The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to offer a greater substantial reduction in body size and improve metabolic marke